En Yi Hew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
En Yi Hew has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Abbas El Sahili
Nanyang Technological University
1 shared publication - Boon Chong Goh
Antimicrobial Resistance Interdisciplinary Research Group, Singapore-Massachusetts Institute of Technology Alliance for Research and Technology Centre, Singapore 138602
1 shared publication - Joash Jun Keat Chu
Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
1 shared publication - Linh Chi Dam
Department of Biomedical Sciences, University of Lausanne
1 shared publication - Nabilah Taqiah Binte Hasnuddin
Singapore Centre for Environmental Life Sciences Engineering, School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
1 shared publication - Scott A. Rice
Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 637551
1 shared publication
Latest Publications
- Open Access
- 28 January 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (2) , 169
Novel Phage Lysin Abp013 against Acinetobacter baumannii
As antimicrobial resistance (AMR) continues to pose an ever-growing global health threat, propelling us into a post-antibiotic era, novel alternative therapeutic agents are urgently required. Lysins are bacteriophage-encoded peptidoglycan hydrolases that display great potential as a novel class of antimicrobials for therapeutics. While lysins against Gram-positive bacteria are highly effective when applied exogenously, it is challenging for lysins to access and cleave the peptidoglycan of Gram-negative bacteria due to their outer membrane. In this study, we identify a novel phage lysin Abp013 against Acinetobacter baumannii. Abp013 exhibited significant lytic activity against multidrug-resistant strains of A. baumannii. Notably, we found that Abp013 was able to tolerate the presence of human serum by up to 10%. Using confocal microscopy and LIVE/DEAD staining, we show that Abp013 can access and kill the bacterial cells residing in the biofilm. These results highlight the intrinsic bacteriolytic property of Abp013, suggesting the promising use of Abp013 as a novel therapeutic agent.
- 28 January 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (2) , 169
Open AccessNovel Phage Lysin Abp013 against Acinetobacter baumannii
As antimicrobial resistance (AMR) continues to pose an ever-growing global health threat, propelling us into a post-antibiotic era, novel alternative therapeutic agents are urgently required. Lysins are bacteriophage-encoded peptidoglycan hydrolases that display great potential as a novel class of antimicrobials for therapeutics. While lysins against Gram-positive bacteria are highly effective when applied exogenously, it is challenging for lysins to access and cleave the peptidoglycan of Gram-negative bacteria due to their outer membrane. In this study, we identify a novel phage lysin Abp013 against Acinetobacter baumannii. Abp013 exhibited significant lytic activity against multidrug-resistant strains of A. baumannii. Notably, we found that Abp013 was able to tolerate the presence of human serum by up to 10%. Using confocal microscopy and LIVE/DEAD staining, we show that Abp013 can access and kill the bacterial cells residing in the biofilm. These results highlight the intrinsic bacteriolytic property of Abp013, suggesting the promising use of Abp013 as a novel therapeutic agent.